Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Kidney Cancer Pipeline Products Market Report Overview

Kidney cancer or renal cancer is a disease in which kidney cells become malignant (cancerous) and grow out of control, forming a tumor. Symptoms include blood in urine, loss of appetite, fever that lasts for weeks, extreme fatigue, anemia, shortness of breath, and bone pain. Treatment includes surgery, radiation therapy, and chemotherapy.

The kidney cancer pipeline market research report provides comprehensive information on the therapeutics under development for kidney cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for kidney cancer and features dormant and discontinued projects.

Kidney Cancer Pipeline Products Market Segmentation by Targets

The key targets in the kidney cancer pipeline products market are Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Cells Expressing Epidermal Growth Factor Receptor, Hepatocyte Growth Factor Receptor, Mast/Stem Cell Growth Factor Receptor Kit, and Vascular Endothelial Growth Factor Receptor 2 among others. Programmed Cell Death 1 Ligand 1 is the leading target in the pipeline.

Kidney Cancer Pipeline Products Market Analysis by Targets

Kidney Cancer Pipeline Products Market Analysis by TargetsFor more target insights into the kidney cancer pipeline products market, download a free report sample

Kidney Cancer Pipeline Products Market Segmentation by Mechanisms of Action

The key mechanisms of action in the kidney cancer pipeline products market are Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Interleukin 10 Receptor Agonist, Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, and Hepatocyte Growth Factor Receptor Inhibitor among others. Programmed Cell Death 1 Ligand 1 Inhibitor is the leading MoA in the pipeline market.

Kidney Cancer Pipeline Products Market Analysis by Mechanisms of Action

Kidney Cancer Pipeline Products Market Analysis by Mechanisms of ActionFor more mechanisms of action insights into the kidney cancer pipeline products market, download a free report sample

Kidney Cancer Pipeline Products Market Segmentation by Routes of Administration

The key routes of administration in the kidney cancer pipeline products market are intravenous, oral, subcutaneous, parenteral, topical, vaginal, and intratumor among others. Intravenous is the leading RoA.

Kidney Cancer Pipeline Products Market Analysis by Routes of Administration

Kidney Cancer Pipeline Products Market Analysis by Routes of AdministrationFor more routes of administration insights into the kidney cancer pipeline products market, download a free report sample

Kidney Cancer Pipeline Products Market Segmentation by Molecule Types

The key molecule types in the kidney cancer pipeline products market are small molecule, monoclonal antibody, cell therapy, synthetic peptide, fusion protein, gene-modified cell therapy, recombinant protein, monoclonal antibody conjugated, oncolytic virus, antisense oligonucleotide, and recombinant vector vaccine among others. The small molecule is the leading molecule type.

Kidney Cancer Pipeline Products Market Analysis by Molecule Types

Kidney Cancer Pipeline Products Market Analysis by Molecule TypesFor more molecule type insights into the kidney cancer pipeline products market, download a free report sample

Kidney cancer Pipeline Products Market - Competitive Landscape

Some of the leading companies in the kidney cancer pipeline products market are Deka Biosciences Inc, Bayer AG, Gilead Sciences Inc, Merck KGaA, Agenus Inc, Alligator Bioscience AB, Alphamab Oncology, Boehringer Ingelheim International GmbH, and Bristol-Myers Squibb Co among others. Deka Biosciences Inc is the leading company in the kidney cancer pipeline products market.

Kidney cancer Pipeline Products Market Analysis by Companies

Kidney cancer Pipeline Products Market Analysis by CompaniesTo know more about the leading players in the kidney cancer pipeline products market, download a free report sample

Kidney cancer Pipeline Products Market Report Overview

Key Targets Programmed Cell Death 1 Ligand 1, Programmed Cell Death Protein 1, Cells Expressing Epidermal Growth Factor Receptor, Hepatocyte Growth Factor Receptor, Mast/Stem Cell Growth Factor Receptor Kit, and Vascular Endothelial Growth Factor Receptor 2
Key Mechanisms of Action Programmed Cell Death 1 Ligand 1 Inhibitor, Cytotoxic To Cells Expressing Epidermal Growth Factor Receptor, Programmed Cell Death Protein 1 Antagonist, Vascular Endothelial Growth Factor Receptor 2 Inhibitor, Interleukin 10 Receptor Agonist, Tumor Necrosis Factor Receptor Superfamily Member 9 Agonist, Cytotoxic To Cells Expressing Receptor Tyrosine Protein Kinase ERBB 2, and Hepatocyte Growth Factor Receptor Inhibitor
Key Routes of Administration Intravenous, Oral, Subcutaneous, Parenteral, Topical, Vaginal, and Intratumor
Key Molecule Type Small Molecules, Monoclonal Antibody, Cell Therapy, Synthetic Peptide, Fusion Protein, Gene-Modified Cell Therapy, Recombinant Protein, Monoclonal Antibody Conjugated, Oncolytic Virus, Antisense Oligonucleotide, and Recombinant Vector Vaccine
Leading Companies Deka Biosciences Inc, Bayer AG, Gilead Sciences Inc, Merck KGaA, Agenus Inc, Alligator Bioscience AB, Alphamab Oncology, Boehringer Ingelheim International GmbH, and Bristol-Myers Squibb Co

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of kidney cancer.
  • The pipeline guide reviews pipeline therapeutics for kidney cancer by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in kidney cancer therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates kidney cancer therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews the latest news related to pipeline therapeutics for kidney cancer

Reasons to Buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolios and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for kidney cancer.
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding the kidney cancer pipeline depth and focus on Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.

4D Pharma Plc
4SC AG
A28 Therapeutics Inc
AbbVie Inc
Actuate Therapeutics Inc
Adicet Bio Inc
Affimed GmbH
Agenus Inc
Alligator Bioscience AB
Almac Discovery Ltd
Alpha-1 Biologics Corp
Alphamab Oncology
Alpine Immune Sciences Inc
Anaveon AG
AntiCancer Inc
Apcure SAS
Apollomics Inc
Aravive Inc
Astellas Pharma Inc
AvenCell Europe GmbH
Avesthagen Ltd
Bavarian Nordic AS
Bayer AG
Beijing Foreland Pharma Co Ltd
Beijing Scitech-MQ Pharmaceuticals Ltd
BeyondSpring Inc
Bio-Thera Solutions Ltd
BioAtla Inc
BioNTech SE
Biosion Inc
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Co
Calviri Inc
CanBas Co Ltd
Canget BioTekpharma LLC
Celldex Therapeutics Inc
Centurion BioPharma Corp
Chongqing Precision Biotech Co Ltd
Clonz Biotech Pvt Ltd
COARE Biotechnology Inc
Coherent Biopharma
Corvus Pharmaceuticals Inc
Cothera Bioscience Pty Ltd
CSPC Pharmaceutical Group Ltd
CureLab Oncology Inc
CytomX Therapeutics Inc
Deciphera Pharmaceuticals Inc
Deka Biosciences Inc
DNAtrix Inc
Duet Therapeutics Inc
Dyadic International Inc
Elevation Oncology Inc
Enara Bio Ltd
Exelixis Inc
Fannin Innovation Studio
Faron Pharmaceuticals Oy
Gilead Sciences Inc
Glycotope GmbH
GSK plc
Guangzhou BeBetter Medicine Technology Co Ltd
Handa Pharmaceuticals LLC
Helixmith Co Ltd
ImmuneOnco Biopharmaceuticals (Shanghai) Co Ltd
ImmunityBio Inc
Imugene Ltd
Incyte Corp
Inmune Bio Inc
Innovative Cellular Therapeutics Co Ltd
IO Biotech Inc
iOmx Therapeutics AG
Jiangxi Jemincare Group Co Ltd
Johnson & Johnson
Jubilant Therapeutics Inc
Kind Pharmaceuticals
Komipharm International Co Ltd
Lantern Pharma Inc
Luye Pharma Group Ltd
MacroGenics Inc
Marino Biotechnology Co Ltd
MaxiVAX SA
MdBioLab
MedAnnex Ltd
Merck & Co Inc
Merck KGaA
Metagone Biotech Inc
Metis Precision Medicine
MicuRx Pharmaceuticals Inc
Midissia Therapeutics Inc
Millennium Pharmaceuticals Inc
Mina Therapeutics Ltd
Mirati Therapeutics Inc
Moleculin Biotech Inc
Multitude therapeutics Inc
Nanjing Aimeifei Biomedical Technology Co Ltd
NanoVation Therapeutics Inc
NeuClone Pty Ltd
Novartis AG
Oncolys BioPharma Inc
Oncovir Inc
OneThree Biotech Inc
Orion Corp
Orpheus Therapeutics Inc
Panorama Researchama Research
Pfizer Inc
PharmaTher Holdings Ltd
Pharmicell Co Ltd
Pharminogen Inc
Portage Biotech Inc
Poseida Therapeutics Inc
Propanc Biopharma Inc
Pyxis Oncology Inc
Qilu Pharmaceutical Co Ltd
Qu Biologics Inc
Quadriga BioSciences Inc
RemeGen Co Ltd
Repertoire Immune Medicines Inc
Rizen (Suzhou) Biosciences Co Ltd
SA Science Inc
Sanofi
Sareum Holdings Plc
Scancell Holdings Plc
Shanghai Escugen Biotechnology Co Ltd
Shanghai Pharmaceutical Group Co Ltd
Shanghai Pharmaceuticals Holding Co Ltd
Shattuck Labs Inc
Shenzhen Chipscreen Biosciences Co Ltd
Shijiazhuang Yiling Pharmaceutical Co Ltd
Sonnet BioTherapeutics Holdings Inc
ST Pharm Co Ltd
Statera Biopharma Inc
Suzhou Stainwei Biotech Inc
Suzhou Zerun New Drug Research and Development Co Ltd
TAE Life Sciences LLC
TotalClarity Inc
UbiVac Inc
Unicyte AG
Vault Pharma Inc
Versameb AG
Wntrix Inc
Xbrane Biopharma AB
Yuhan Corp
ZielBio Inc
Zylem Biosciences Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Kidney Cancer (Renal Cell Cancer) – Overview

Kidney Cancer (Renal Cell Cancer) – Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Kidney Cancer (Renal Cell Cancer) – Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

ssessment by Route of Administration

Assessment by Molecule Type

Kidney Cancer (Renal Cell Cancer) – Companies Involved in Therapeutics Development

Kidney Cancer (Renal Cell Cancer) – Drug Profiles

Kidney Cancer (Renal Cell Cancer) – Dormant Projects

Kidney Cancer (Renal Cell Cancer) – Discontinued Products

Kidney Cancer (Renal Cell Cancer) – Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

Table

List of Tables

Number of Products under Development for Kidney Cancer (Renal Cell Cancer), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Kidney Cancer (Renal Cell Cancer) – Dormant Projects, 2022

Kidney Cancer (Renal Cell Cancer) – Discontinued Products, 2022

Figures

List of Figures

Number of Products under Development for Kidney Cancer (Renal Cell Cancer), 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

Frequently asked questions

Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update thematic reports
Currency USD
$2,500

Can be used by individual purchaser only

$7,500

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update in real time.

  • Access a live Kidney Cancer (Renal Cell Cancer) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.